$MRAM

Dougherty Sean Michael sold $147K of MRAM

Dougherty Sean Michael (Vice President, Sales) sold 7,691 shares of EVERSPIN TECHNOLOGIES INC. (MRAM) at $19.08 ($0.15M total) on 2026-10-02.

Original reporting
SEC EDGAR · Dougherty Sean Michael
Published Oct 5, 2026, 8:55 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 5, 2026, 8:58 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$MRAM
Neutral
medium confidence
Mentioned
$MRAM
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$MRAMNeutralLow
01

Why it matters

The transaction is a routine insider sale with limited market impact.

02

Market read

Small insider sale; unlikely to move the stock materially.

03

What to watch

Potential upcoming corporate actions or financing that prompted the sale are not disclosed.

Relevance 4/10Novelty 3/10Timing: today

Background

SEC Form 4 filing discloses an insider transaction for EverSpin Technologies (ticker MRAM).

Company-level read

Ticker impact

$MRAMNeutralMedium confidence
Context

Vice President Sean Michael Dougherty sold 7,691 shares of EverSpin Technologies at $19.08 each, total $146.7K.

Expected impact

likely modest downward pressure as market prices the insider sell.

Evidence & confidence

The sale size is small relative to float and typical trading volume, limiting impact.

Market effects

None significant; insider activity does not affect broader semiconductor sector.

No regional impact.

Low relevance globally.

Counterpoint

The sale could be a signal of insider concern, but size is too small to act on.

Key entities

  • Sean Michael Dougherty

    Vice President, Sales at EverSpin Technologies.

  • EverSpin Technologies Inc.

    Manufacturer of magnetic random-access memory (MRAM) products.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$MUMed

Dow, S&P 500, Nasdaq Futures Slip As Trump Calls Iran’s Peace Proposal ‘Totally Unacceptable’ — MU, SNDK, MRAM, MLTX Stocks In Focus

U.S. stock futures fell Sunday night after President Trump rejected Iran's peace proposal, raising concerns about global energy supplies. Dow, S&P 500, and Nasdaq futures declined, while oil prices rose. Micron (MU) and Sandisk (SNDK) shares surged over 5% due to high demand for memory chips. Everspin (MRAM) and MoonLake (MLTX) also saw significant gains.

$MRAMMed

Everspin Reports Unaudited Second Quarter 2026 Financial Results

EVERSPIN TECHNOLOGIES INC. (MRAM) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Everspin Reports Unaudited Second Quarter 2026 Financial Results Chandler, AZ, August 5, 2026 —Everspin Technologies, Inc. (NASDAQ: MRAM), the world’s leading developer and manufacturer of Magnetoresistive Random Access Memory (MRAM) persistent memory solutions, toda

$MRAMMed

Everspin stock surges 14% on MaxLinear AI server partnership

Everspin Technologies (NASDAQ:MRAM) shares rose 14% and MaxLinear (NYSE:MXL) gained 9% after both firms announced an MOU to evaluate next-generation memory architectures for AI servers. The plan combines Everspin’s persistent low-latency MRAM with MaxLinear’s storage compression, encryption and acceleration platform, targeting data-intensive workloads and market development for cloud and enterprise customers.

$NVDAMedAI 9/10

MarketBeat Week in Review – 05/18 - 05/22

Stocks rose into the week’s close, with NVIDIA (NVDA) results and forward guidance cited as evidence of tangible demand for AI infrastructure. Retail stocks showed a mixed consumer backdrop amid inflation concerns. U.S. markets were closed Monday for Memorial Day. The review also highlighted items including SpaceX’s public S-1 filing and a Phase 2 Alzheimer’s trial miss at Biogen (BIIB).